Qiagen N.V. is a Netherlands-based holding company and leading global provider of Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical developm... Qiagen N.V. is a Netherlands-based holding company and leading global provider of Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Founded in 1984 in Germany and headquartered in Venlo, Netherlands, it specializes in technologies that extract, purify, amplify, and analyze DNA, RNA, and proteins from various samples like blood and tissue. The company operates through two main segments: Molecular Diagnostics, focusing on oncology, infectious diseases, and immune monitoring; and Life Sciences, supporting genomics, transcriptomics, proteomics, forensics, and biotechnology. Notable products include Real-Time PCR instrumentation, nucleic acid amplification kits, automated sample preparation systems, next-generation sequencing tools, and bioinformatics software like QIAGEN Clinical Insights. Qiagen N.V. serves over 500,000 customers worldwide across healthcare, pharma, academia, and more, with 5,700 employees in 35 subsidiaries spanning 25 countries and key regions including Americas, EMEA, and Asia-Pacific. Its innovations drive advances in personalized medicine, cancer genomics, infectious disease detection, and food safety, positioning it as a vital player in life sciences research and clinical applications.
We have not yet reviewed Qiagen's disclosures for Group Entities data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.